Your browser is no longer supported. Please, upgrade your browser.
Settings
SRNE Sorrento Therapeutics, Inc. daily Stock Chart
SRNE [NASD]
Sorrento Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.64 Insider Own0.30% Shs Outstand76.56M Perf Week-7.89%
Market Cap133.98M Forward P/E- EPS next Y-0.65 Insider Trans- Shs Float40.34M Perf Month0.00%
Income-34.80M PEG- EPS next Q-0.23 Inst Own17.00% Short Float7.54% Perf Quarter0.00%
Sales15.80M P/S8.48 EPS this Y2.50% Inst Trans-5.21% Short Ratio4.26 Perf Half Y-57.83%
Book/sh1.31 P/B1.34 EPS next Y39.30% ROA-9.90% Target Price13.50 Perf Year-75.80%
Cash/sh0.71 P/C2.46 EPS next 5Y37.00% ROE-45.00% 52W Range1.50 - 8.35 Perf YTD-64.29%
Dividend- P/FCF- EPS past 5Y-30.00% ROI-75.50% 52W High-79.04% Beta1.71
Dividend %- Quick Ratio0.80 Sales past 5Y72.80% Gross Margin87.10% 52W Low16.67% ATR0.11
Employees154 Current Ratio0.80 Sales Q/Q422.20% Oper. Margin- RSI (14)45.49 Volatility5.65% 6.89%
OptionableYes Debt/Eq0.29 EPS Q/Q78.30% Profit Margin- Rel Volume0.95 Prev Close1.85
ShortableYes LT Debt/Eq0.29 EarningsSep 25 AMC Payout- Avg Volume713.11K Price1.75
Recom1.50 SMA20-0.78% SMA50-5.07% SMA200-45.55% Volume686,515 Change-5.41%
May-22-17Reiterated Rodman & Renshaw Buy $30 → $20
May-22-17Reiterated FBR & Co. Outperform $13 → $9
Oct-03-16Initiated ROTH Capital Buy
Apr-06-16Reiterated FBR Capital Outperform $21 → $16
Mar-16-16Reiterated FBR Capital Outperform $22 → $21
Dec-22-15Initiated FBR Capital Outperform $22
Dec-07-15Resumed Rodman & Renshaw Buy $45
Aug-03-15Resumed MLV & Co Buy $34
Jul-29-15Reiterated Brean Capital Buy $17 → $26
May-28-15Initiated Brean Capital Buy $17
Mar-17-15Reiterated H.C. Wainwright Buy $13 → $20
Oct-02-14Initiated H.C. Wainwright Buy $11
Jun-19-14Initiated MLV & Co Buy $9
Dec-03-13Initiated Aegis Capital Buy $40
Nov-21-13Initiated CRT Capital Buy $11
Sep-19-17 08:00AM  Sorrento Therapeutics, Inc. To Present At Cantor Global Healthcare Conference (09/25/17 - 2:25 PM ET) PR Newswire -5.41%
Sep-12-17 06:00AM  FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido; PDUFA Date Set For February 28, 2018 PR Newswire
Sep-08-17 04:03PM  Sorrento Therapeutics, Inc. To Present At 19th Rodman And Renshaw Global Investment Conference (09/11/17 - 17:30 ET) PR Newswire
Aug-31-17 09:09PM  ETFs with exposure to Sorrento Therapeutics, Inc. : September 1, 2017 Capital Cube
07:10AM  Featured Company News - Sorrento Submits NDA for ZTlido Next-Gen Lidocaine Patch; Intends to File an MAA in Europe ACCESSWIRE
Aug-29-17 06:00AM  Sorrento Therapeutics, Inc. Submits NDA For ZTlido Next-Generation Lidocaine Patch PR Newswire -7.14%
Aug-25-17 12:29PM  Sorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube
Aug-21-17 05:21PM  Sorrento Contributes To The Formation Of Celularity, Inc. For Breakthrough Placental Therapeutic Platform In Consortium With Leading Pharmaceutical Companies PR Newswire
04:48PM  Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform PR Newswire
04:22PM  Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform CNW Group
Jul-17-17 08:50AM  Today's Research Reports on Stocks to Watch: Sorrento Therapeutics and Omeros Corporation Accesswire
Jun-30-17 03:24PM  ETFs with exposure to Sorrento Therapeutics, Inc. : June 30, 2017 Capital Cube
Jun-29-17 12:22PM  Sorrento Therapeutics Announced FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain PR Newswire
Jun-26-17 07:00AM  Semnur Pharmaceuticals, Inc., Announces Successful Phase 1 / 2 Trial in Patients with Radicular Pain for Its Lead Product, SP-102 PR Newswire +13.51%
Jun-16-17 04:21PM  ETFs with exposure to Sorrento Therapeutics, Inc. : June 16, 2017 Capital Cube +8.11%
Jun-14-17 02:29PM  Sorrento Therapeutics Announces Dismissal Of Lawsuits PR Newswire +9.38%
09:00AM  Sorrento Therapeutics' Pain Subsidiary, SCILEX Pharmaceuticals, Announces Positive Data from Head to Head Adhesion Study with its Lead Product, ZTlido PR Newswire
Jun-13-17 09:00AM  Sorrento Therapeutics Contributes to the Formation of Celularity, Inc. PR Newswire
Jun-05-17 02:47PM  ETFs with exposure to Sorrento Therapeutics, Inc. : June 5, 2017 Capital Cube -6.06%
Jun-02-17 10:05AM  Sorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube +6.45%
May-04-17 10:17AM  Sorrento Therapeutics Announces the Completion of GMP Manufacturing Plant in Suzhou, China to Support its Growing Antibody-Drug Conjugate (ADC) Pipeline and Service Business PR Newswire
09:41AM  Sorrento Therapeutics Announces the Completion of GMP Manufacturing Plant in Suzhou, China to Support its Growing Antibody-Drug Conjugate (ADC) Pipeline and Service Business PR Newswire
09:41AM  Sorrento Therapeutics Announces the Completion of GMP Manufacturing Plant in Suzhou, China to Support its Growing Antibody-Drug Conjugate (ADC) Pipeline and Service Business CNW Group
May-02-17 04:40PM  ETFs with exposure to Sorrento Therapeutics, Inc. : May 2, 2017 Capital Cube
Apr-28-17 09:00AM  Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics PR Newswire -7.14%
09:00AM  Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics CNW Group
Apr-20-17 02:30PM  ETFs with exposure to Sorrento Therapeutics, Inc. : April 20, 2017 Capital Cube
Apr-19-17 04:05PM  Sorrento Announces Closing of Public Offering of Common Stock PR Newswire
Apr-13-17 11:30AM  Sorrento Therapeutics Gears Up for Secondary Offering 24/7 Wall St. -38.98%
10:13AM  Sorrento's stock plunges on heavy volume after stock offering prices at deep discount MarketWatch
09:58AM  Sorrento Announces Pricing of Public Offering of Common Stock PR Newswire
Apr-12-17 04:00PM  Sorrento Announces Proposed Public Offering of Common Stock PR Newswire
Apr-10-17 01:58PM  ETFs with exposure to Sorrento Therapeutics, Inc. : April 10, 2017 Capital Cube
Apr-03-17 01:25PM  Sorrento Therapeutics anti-CEA CAR-T Demonstrates Promising Clinical Activity and Safety in Phase Ib Clinical Trial PR Newswire -8.86%
Mar-31-17 01:04PM  SORRENTO THERAPEUTICS, INC. Financials
Mar-29-17 08:36PM  ETFs with exposure to Sorrento Therapeutics, Inc. : March 30, 2017 Capital Cube
08:36PM  ETFs with exposure to Sorrento Therapeutics, Inc. : March 30, 2017
Mar-24-17 09:36AM  Sorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 24, 2017 Capital Cube
09:36AM  Sorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 24, 2017
06:05AM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Mar-22-17 06:06AM  SORRENTO THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
Mar-21-17 05:27PM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Mar-20-17 08:01AM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  Sorrento and Wildcat Announce Resolution PR Newswire
08:00AM  Sorrento and Wildcat Announce Resolution CNW Group
Mar-09-17 05:01PM  Sorrento Therapeutics to Present at 29th Annual ROTH Conference PR Newswire
Feb-15-17 12:25PM  Insider Buys Shares of Sorrento Therapeutics GuruFocus.com
Feb-06-17 08:55AM  Jump in Insider Buying at Macquarie Infrastructure after Hedgeye Recommends Shorting the Stock, Spontaneous Insider Sale at Apple Inc. (AAPL), Plus Other Insider Trading Insider Monkey +7.84%
Jan-23-17 09:00AM  The Life Sciences Report Examines the Inclusion of Sorrento Therapeutics on Streetwise Reports' 2017 Small-Cap Biotech Watchlist Marketwired
Jan-20-17 02:01PM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits
Jan-09-17 02:11PM  ETFs with exposure to Sorrento Therapeutics, Inc. : January 9, 2017 Capital Cube
02:11PM  ETFs with exposure to Sorrento Therapeutics, Inc. : January 9, 2017
11:32AM  Sorrento Therapeutics, Inc. Value Analysis (NASDAQ:SRNE) : January 9, 2017
09:00AM  Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido PR Newswire
Jan-06-17 07:36AM  Sorrento Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRNE-US : January 6, 2017
Jan-05-17 01:05PM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclos +10.09%
Dec-22-16 01:10PM  These 5 Stocks Under $10 Could Make You a Lot of Money
Dec-21-16 08:30AM  Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance Business Wire
Dec-08-16 03:15PM  ETFs with exposure to Sorrento Therapeutics, Inc. : December 8, 2016
Dec-05-16 07:00AM  Sorrento Subsidiary, SCILEX Pharmaceuticals Announces Key Endpoints Met in Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido PR Newswire
Dec-01-16 07:26AM  Sorrento's TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for Treatment of Hematological Malignancies PR Newswire
Nov-29-16 05:25PM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material
Nov-28-16 05:56PM  Sorrento Therapeutics, Inc. Secures $75 Million Loan Facility PR Newswire -6.67%
Nov-23-16 01:32PM  ETFs with exposure to Sorrento Therapeutics, Inc. : November 23, 2016
Nov-22-16 11:18AM  Sorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016
Nov-16-16 04:59PM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S
03:24PM  Sorrento's TNK Therapeutics Subsidiary to Acquire Virttu Biologics PR Newswire
Nov-14-16 06:00AM  Sorrento Therapeutics to Attend Jefferies and ROTH Investor Conferences PR Newswire +5.65%
Nov-09-16 03:40PM  SORRENTO THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Nov-08-16 04:20PM  Sorrento Therapeutics Closes Acquisition of Scilex PR Newswire +6.80%
04:18PM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material
Nov-01-16 01:57PM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure
Oct-17-16 08:44AM  Sorrento Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRNE-US : October 17, 2016
Oct-03-16 08:14AM  Coverage initiated on Sorrento Therapeutics by ROTH Capital +5.68%
Sep-27-16 08:00AM  ARK Animal Health, a Subsidiary of Sorrento Therapeutics, Announces Submission of Two Major Technical Sections of a New Animal Drug Application PR Newswire
Sep-22-16 11:58AM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-13-16 04:37PM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S
08:00AM  Sorrento Appoints Miranda Toledano As Executive Vice President of Corporate Development, and President of LA Cell PR Newswire
Sep-07-16 05:16PM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements a
Aug-30-16 04:01PM  Sorrento Therapeutics to Present at Two Upcoming Conferences in New York City PR Newswire
Aug-23-16 09:26AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Sorrento Therapeutics, Inc. - SRNE Accesswire
07:11AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sorrento Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Aug-17-16 06:05AM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S
Aug-16-16 04:19PM  [$$] Sorrento Subsidiary Acquires Semnur for Up to $200M at The Wall Street Journal
Aug-15-16 06:34PM  Scintilla Pharmaceuticals, Inc., a Subsidiary of Sorrento Therapeutics, Inc., to Acquire Semnur Pharmaceuticals, Inc. to Further Deepen its Pain Management Pipeline PR Newswire +6.44%
02:50PM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:00AM  Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene, to Join Sorrento as Chief Medical Officer and President of Clinical Development PR Newswire
Aug-09-16 10:20AM  Medovex Corp. Completes Financing Led by Sorrento Therapeutics, Inc. Marketwired
Aug-08-16 11:18AM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S
09:00AM  Scintilla Pharmaceuticals, a Subsidiary of Sorrento Therapeutics, to Acquire SCILEX Pharmaceuticals to Add a Late-Stage Asset to Bolster its Pain Management Business PR Newswire
Aug-02-16 09:00AM  Sorrento to Form Joint Venture with CHA Biotech to Develop and Commercialize Natural Killer Cell Therapies PR Newswire
Aug-01-16 04:32PM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
07:00AM  Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors PR Newswire
Jul-20-16 08:22AM  Sorrento Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRNE-US : July 20, 2016
Jul-11-16 09:11AM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S
09:00AM  Sorrento and Servier Enter Into Exclusive Worldwide License and Collaboration Agreement for Development and Commercialization of Anti-PD-1 Antibody PR Newswire
Jul-07-16 03:41PM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Other Events +7.45%
08:11AM  Sorrento Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRNE-US : July 7, 2016
Jul-01-16 04:16PM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement +6.25%
Jun-30-16 05:12PM  SORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -5.88%
Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases. The company offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain at end-stage disease. Its preclinical human therapeutic antibodies include antibody drug conjugates, bispecific approaches, and T-Cell Receptor, as well as Chimeric Antigen Receptor-T Cell (CAR-T) for adoptive cellular immunotherapy for the treatment of solid and liquid tumors. It is also involved in the development of T-007, an anti-CD38 CAR-T cellular therapy for the treatment of multiple myeloma, as well as for additional potential indications, such as amyloidosis and graft-versus-host disease; and T-009, an anti-CD123 CAR-T cellular therapy for the treatment of acute myelogenous leukemia. The company has license and collaboration agreement with Les Laboratoires Servier for the development, manufacture, and commercialization of products using its human immuno-oncology anti-PD-1 mAb STI-A1110. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ji HenryPresident and CEOJun 15Buy1.8129,00152,56229,001Jun 15 04:20 PM
SHAH JAISIMDirectorJun 15Buy1.7910,00217,904112,633Jun 15 04:13 PM
ABG Management Ltd10% OwnerApr 19Buy2.00550,0001,100,0001,991,441Apr 21 07:16 AM
Ji HenryPresident and CEOApr 19Buy2.00100,000200,000139,776Apr 19 04:12 PM
ABG Management Ltd10% OwnerApr 13Buy2.002,500,0005,000,0001,500,000Apr 17 09:59 PM
Ji HenryPresident and CEOFeb 22Buy5.602,00011,20039,776Feb 22 05:08 PM
SHAH JAISIMDirectorFeb 03Buy5.1510,00051,500102,631Feb 03 07:44 PM
ZELDIS JEROME BSee RemarksFeb 03Buy5.1510,00051,50010,000Feb 03 07:43 PM
Wu Yue AlexanderDirectorFeb 03Buy5.155,00025,7505,000Feb 03 07:51 PM
Janda KimDirectorFeb 03Buy5.153,00015,4503,000Feb 03 07:50 PM
Su JeffreyExecutive VP and COOFeb 03Buy5.154,00020,60013,000Feb 03 07:49 PM
Herde KevinExecutive VP and CFOFeb 03Buy5.153,00015,4507,000Feb 03 07:48 PM
Ji HenryPresident and CEOFeb 03Buy5.1520,000103,00037,776Feb 03 07:47 PM
Ng George KSee RemarksFeb 03Sale5.1540,000206,00049,338Feb 03 07:46 PM